Prescribe an SGLT2 inhibitor for heart failure in the absence of diabetes?

被引：2
作者：
Koenigsberger, Debra [1 ]
Marquez, Alexander [1 ]
Hughes, Pamela R. [1 ]
Mullen, Rebecca [2 ]
机构：
[1] Nellis AFB Family Med Residency, Las Vegas, NV USA
[2] Univ Colorado, Dept Family Med, Denver, CO 80202 USA
来源：
JOURNAL OF FAMILY PRACTICE | 2021年 / 70卷 / 06期
关键词：
RISK;
D O I：
10.12788/jfp.0235
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
[No abstract available]
引用
收藏
页码：E7 / E9
页数：3
相关论文
共 50 条
  • [31] SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
    Neuen, Brendan L.
    Young, Tamara
    Heerspink, Hiddo J. L.
    Neal, Bruce
    Perkovic, Vlado
    Billot, Laurent
    Mahaffey, Kenneth W.
    Charytan, David M.
    Wheeler, David C.
    Arnott, Clare
    Bornpoint, Severine
    Levin, Adeera
    Jardine, Meg J.
    LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (11) : 845 - 854
  • [32] SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation
    Komatsu, Shiho
    Nomiyama, Takashi
    Numata, Tomohiro
    Kawanami, Takako
    Hamaguchi, Yuriko
    Iwaya, Chikayo
    Horikawa, Tsuyoshi
    Fujimura-Tanaka, Yuki
    Hamanoue, Nobuya
    Motonaga, Ryoko
    Tanabe, Makito
    Inoue, Ryuji
    Yanase, Toshihiko
    Kawanami, Daiji
    ENDOCRINE JOURNAL, 2020, 67 (01) : 99 - 106
  • [33] SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review
    Thomas, Merlin C.
    Neuen, Brendon L.
    Twigg, Stephen M.
    Cooper, Mark E.
    Badve, Sunil, V
    ENDOCRINE CONNECTIONS, 2023, 12 (08)
  • [34] SGLT2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis: A Case Report
    Wang, Katherine M.
    Isom, Robert T.
    KIDNEY MEDICINE, 2020, 2 (02) : 218 - 221
  • [35] Heart Failure with Preserved Ejection Fraction and Obstructive Sleep Apnea: A Novel Paradigm for Additional Cardiovascular Benefit of SGLT2 Inhibitors in Subjects With or Without Type 2 Diabetes
    Monda, Vincenzo Maria
    Gentile, Sandro
    Porcellati, Francesca
    Satta, Ersilia
    Fucili, Alessandro
    Monesi, Marcello
    Strollo, Felice
    ADVANCES IN THERAPY, 2022, 39 (11) : 4837 - 4846
  • [36] Search for a Functional Genetic Variant Mimicking the Effect of SGLT2 Inhibitor Treatment
    Wang, Siqi
    Said, M. Abdullah
    Groot, Hilde E.
    van der Most, Peter J.
    Thio, Chris H. L.
    van de Vegte, Yordi J.
    Verweij, Niek
    Snieder, Harold
    van der Harst, Pim
    GENES, 2021, 12 (08)
  • [37] Great Debate: SGLT2 inhibitors should be first-line treatment in heart failure with reduced ejection fraction
    Packer, Milton
    Cleland, John G. F.
    Bauersachs, Johann
    EUROPEAN HEART JOURNAL, 2024, 45 (25) : 2186 - 2196
  • [38] Prevalence of genitourinary symptoms in people with type 2 diabetes initiated with SGLT2 inhibitors
    Viswanathan, Vijay
    Samraj, Divyabharathi
    Baid, Leela
    Kumpatla, Satyavani
    INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES, 2024,
  • [39] The current role of SGLT2 inhibitors in type 2 diabetes and beyond: a narrative review
    Scheen, Andre J.
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2023, 18 (04) : 271 - 282
  • [40] SGLT2 inhibition in patients with type 2 diabetes and cardiovascular diseases: which are the benefits?
    Diaconu, Camelia
    Salmen, Teodor
    Gaman, Mihnea A.
    Bratu, Ovidiu G.
    Mischianu, Dan
    Marcu, Radu D.
    Suceveanu, Andra I.
    Costache, Raluca S.
    Stoian, Anca Pantea
    ROMANIAN JOURNAL OF MILITARY MEDICINE, 2019, 122 (01) : 16 - 21
12345